Join
Live feed
·
PRReleasevia Quantisnow
Bristol-Myers Squibb Company logo
Nektar Therapeutics logo

Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma

ByQuantisnow·Wall Street's wire, on your screen.
BMY· Bristol-Myers Squibb CompanyNKTR· Nektar Therapeutics
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BMY (Bristol-Myers Squibb Company), NKTR (Nektar Therapeutics) and more on Quantisnow.